NIMH Outreach Partner in Connecticut/Information on Clinical Trials
NAMI Connecticut and the National Institute of Mental Health
NAMI Connecticut is the state’s Outreach Partner for the National Institute of Mental Health (NIMH). As an Outreach Partner, we have access to the latest science-based educational materials and have a responsibility to distribute NIMH materials statewide. We also have information on new clinical trials. NIMH materials are on hand at the NAMI Connecticut office and are also made available at conferences, educational programs and to anyone who requests information. For a full list of publications, as well as a description of the NIMH Outreach Partnership Program, please see the Resources page on our site. You can also contact Janice at email@example.com if you have any questions.
Generalized Anxiety Disorder Research at the Anxiety Disorders Center
The Anxiety Disorders Center at Hartford Hospital/Institute of Living is conducting research on an experimental treatment for Generalized Anxiety Disorder (GAD).
These studies are open to adults ages 18 and older who have GAD. People with GAD often report that they worry about bad things that might happen to themselves or to others, and that they cannot stop themselves from worrying. In order to participate in this research, you must be able to travel to The Institute of Living in Hartford, CT. All of the studies described below compensate you for your time and effort.
Brain Scan Study:
In this study, we are investigating ways to reliably activate the brain regions associated with GAD. Participation involves coming into the clinic for some interviews and questionnaires as well as completing a brain scan using functional magnetic resonance imaging (fMRI), during which we examine how your brain responds to different tasks. Enrolled participants will be compensated $20 per hour for their time up to a maximum of $160. Participants who complete the brain scan may also win additional earnings for tasks completed during this portion of the study.
TMS Treatment Study:
In this study we are investigating whether Transcranial Magnetic Stimulation (TMS) is an effective treatment for GAD. TMS is an FDA-approved therapy for treating major depressive disorder (MDD). It is a non-invasive procedure that applies a magnetic pulse on the scalp. This treatment has been shown to lead to improvements in neuropsychiatric functioning. As part of this study you will also complete a brain scan using magnetic resonance imaging (MRI). Information from the brain scan will be used to guide the TMS treatment. Study participants will be randomly assigned (like a coin toss) to one of two conditions: TMS treatment or a placebo TMS condition during which no magnetic pulse will be received. This study is open to adults aged 18 and older with excessive anxiety and worry who meet study criteria. This experimental treatment is offered at no charge to participants and financial compensation is offered for non-treatment study visits.
If you would like more information or would like to participate in either of these studies, please contact:
Laura Bragdon, M.A.
Or visit the Hartford Hospital/Institute of Living Study Website
VABHS Is Looking for Study Participants
The VA Boston Healthcare System is working with the Harvard Medical School on a genetics study related to schizophrenia.
Since schizophrenia is hereditary, there is likely a gene or sequence of genes within the family tree that play a central role in causing this debilitating disease. Their study is designed to help determine the underlying genetic variables responsible for schizophrenia and to use this information to help develop improved methods for managing symptoms and to eventually find a cure. The sponsor of the study, Amgen, is a pioneer in the development of therapeutic products derived from genetic research which have already helped millions of people around the world in the fight against cancer, kidney disease, and other serious illnesses.
They are currently seeking to identify ten families with a pattern of schizophrenia (3 or more members diagnosed with the disease).
Please click here for information about the study.
If you have any questions, or wish to participate, please contact:
Lynn E. DeLisi MD, Study Investigator
Email GeneticsResearchVA@gmail.com or call (774)826-3155
(Please include name, age and preferred method of contact)
NATIONWIDE RECRUITMENT: BIPOLAR DISORDER ADULT RESEARCH STUDY: BIPOLAR DISORDER & RILUZOLE
(Outpatient or Inpatient: 8 weeks) This study of Riluzole (an FDA-approved drug for Lou Gehrig’s disease, ALS) tests how this drug affects glutamate in the brain and improves treatment-resistant depressive symptoms (failure to reduce symptoms after taking two or more antidepressants.) Recruiting ages 18-70.
For more information on research conducted by the National Institute of Mental Health in Bethesda, MD, please click the link below:
YALE RESEARCH STUDIES ON SCHIZOPHRENIA.
Yale Research is interested in cognitive neuroscience of psychiatric illness. We seek to better understand, at the neural system level, the mechanisms behind cognitive and affective deficits in neuropsychiatric illness. Specifically, the research in our group focuses on understanding these processes in schizophrenia, bipolar illness and addiction. We use a combination of tools to better understand the underlying systems involved in processing affective stimuli and their interaction with circuits involved in goal-directed cognitive operations such as working memory.
HAVE YOU BEEN DIAGNOSED WITH SCHIZOPHRENIA?
We are conducting brain imaging studies using state of the art neuroimaging techniques. We are recruiting adults who may meet diagnostic criteria for schizophrenia.
You might qualify if you meet the following criteria:
1. Age 18-55
2. No major medical illness
3. Not diagnosed with depression
4. Not using drugs, or consuming a lot of alcohol
- This study lasts up to 2 weeks and will take up to 10 hours to complete.
- Study will include a fMRI scan, blood test and interviews.
- Compensation is provided for your participation.
Contact: Nicole P. Santamauro, M.A.
Research Project Coordinator
Yale University School of Medicine
Department of Psychiatry
Click HERE for a Full-Color Flyer suitable for posting
Yale Research Clinic Studies on Obsessive-Compulsive Disorder (OCD)
The following studies are investigating the neurobiological and behavioral markers of Obsessive-Compulsive Disorder (OCD), all in the hopes of better understanding the disorder so that providers may offer better treatment to people struggling with OCD.
1. A Double-blind study of Riluzole Augmentation in Serotonin Reuptake Inhibitor- Refractory Obsessive-Compulsive Disorder and Depression
This is a treatment study for people with OCD who haven’t gotten a good response from medications they’ve tried so far.
2. Biomarkers of clinical subtype and treatment response in obsessive-compulsive disorder
This is a non-treatment study for people with OCD who are not on any medication but have been diagnosed with OCD. It’s mainly an imaging study (MRI/MRS/fMRI) but also has an optional genetic component to it.
3. Pilot Study of Serotonin 1B Receptor Funnction in Euthymic, Medication Free Subjects with Obsessive Compulsive Disorder
This is another non-treatment study for people with OCD who are not on any medication but have been diagnosed with OCD. It’s an imaging study using PET Imaging Technology.
To view a full color flyer suitable for printing and posting, go to: https://org.salsalabs.com/o/1650/images/Yale_OCD_Study_Flyer.pdf
To read more about each of these studies, visit: http://www.ocd.yale.edu/participate/with_ocd.aspx
To obtain more information, please contact the Yale OCD Research Clinic at: (203) 974-7523, or www.ocd.yale.edu
NATIONWIDE RECRUITMENT: DEPRESSION ADULT RESEARCH STUDY
RAPID ANTIDEPRESSANT EFFECTS OF KETAMINE
Individuals who have been diagnosed with major depression may be able to participate in a trial designed to understand the causes of depression and rapid antidepressant response. Specifically, NIMH is testing whether ketamine, a drug that affects glutamate in the brain, will improve symptoms of depression within a matter of hours.
Individuals who are 18-65 years of age and have been diagnosed with major depression (unipolar) and previously failed to respond to treatment may be eligible for an inpatient study designed to bring about a rapid antidepressant effect.
After completion of the study the participant is transitioned back to a clinician in the community. All research participation is without cost and NIMH will cover all transportation costs from anywhere in the United States. Compensation is provided for study procedures.
For more information, please call 1-877-MIND-NIH (1-877-646-3644) or email firstname.lastname@example.org.
National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services
For more information on research conducted by the NIMH in Bethesda, MD click here http://patientinfo.nimh.nih.gov.
Notice of an important study being conducted by the Institute of Living at Hartford Hospital
Have you been diagnosed with Major Depression, Bipolar Disorder or Schizophrenia? Have your symptoms not improved with your current medication? Dr. John Goethe at The Institute of Living/Hartford Hospital is offering screenings for participation in clinical research studies to assess whether investigational drugs may be useful, safe and well-tolerated for the treatment of these disorders. Participants will receive a study-related psychiatric evaluation and the study drugs at no cost. Compensation for time and travel is provided.
For more information, please contact:
Katherine Karbowski, Clinical Study Coordinator
Institute of Living/Hartford Hospital
200 Retreat Avenue
Hartford, CT 06106
Notice of an important study being conducted by the Juvenile Bipolar Research Foundation (JBRF)
Intranasal Ketamine in the Treatment of Pediatric Bipolar Disorder (Ages 6-12, NY Tri-State Area)
The Juvenile Bipolar Research Foundation is recruiting children to participate in a placebo controlled clinical trial in which they will receive 4 administrations of intranasal ketamine during a short, in-home protocol. Research leading up to this study delineated a particularly severe and treatment resistant form of the illness as well as a hypothesis of the neurological underpinnings of the disorder. Research informed investigators that ketamine: a drug known to reduce fear sensitization and lower core body temperature may be an ideal treatment for the condition. A 4+ year pilot study produced a reduction of symptoms primary to the condition for those children who participated. The current IRB/FDA approved study is intended to document evidence of the observed treatment response.
More information can be found at www.jbrf.org/ketamine-clinical-trial/
A flyer for the study with relevant links can be found at http://p0.vresp.com/eeOhFd
If you are interested in participating in this study, please contact the JBRF directly. Their contact info is listed on their website, above.
Nationwide Recruitment: Bipolar Disorder Pediatric Research Study – Clinical Trial of Citalopram and Methylphenidate in Severe Mood Dysregulation
This study is testing the effectiveness of methylphenidate plus citalopram vs. methylphenidate plus placebo for decreasing irritability in children with severe mood dysregulation (SMD). Children with SMD display chronic anger, sadness, or irritability, as well as hyperarousal (such as insomnia, distractibility, hyperactivity) and extreme responses to frustration (such as frequent, severe temper tantrums).
Children ages seven to 17 with SMD may be eligible to participate in this 12- to 15-week inpatient or outpatient study. This study has four phases. During Phase I, participants are gradually withdrawn from all current psychotropic medications. Phase II is a one-week psychotropic medication-free period. During Phase III, which lasts two weeks, participants are treated with methylphenidate alone. Phase IV lasts for eight weeks. During this time, participants continue methylphenidate treatment and are randomly assigned to also receive either citalopram or placebo.
At the end of the study, those who received methylphenidate plus placebo will have the opportunity to receive methylphenidate plus active citalopram if clinically appropriate.
All procedures and medications associated with the research are provided at no cost to participants, and transportation expenses are reimbursed by NIMH. Schooling will be provided while on the inpatient unit or in day treatment. To find out more information, please call (301) 496-8381 or email email@example.com
National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services
For more information on research conducted by the National Institute of Mental Health in Bethesda, MD click the following link: http://patientinfo.nimh.nih.gov
Nationwide Recruitment: Bipolar Disorder (Adult) Research Study – Antidepressant (Rapid) Effects of Ketamine
Individuals who have been diagnosed with bipolar disorder may be able to participate in a trial designed to understand the causes of depression and rapid antidepressant response. Specifically, this trial is testing whether ketamine, a drug that affects glutamate in the brain will improve symptoms of depression within a matter of hours.
Individuals who are 18 to 65 years of age and have been diagnosed with bipolar disorder and previously failed to respond to treatment may be eligible for an inpatient trial designed to bring about a rapid antidepressant effect. After completion of the study the participant is transitioned back to a clinician in the community. In addition, all research participation is without cost and NIMH covers all transportation costs from anywhere in the United States. Compensation is provided for study procedures.
To find out more information, please call 1-877-MIND-NIH (1-877-646-3644) or email firstname.lastname@example.org
National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services.
For more information on research conducted by the National Institute of Mental Health in Bethesda, MD: http://patientinfo.nimh.nih.gov
NIMH Information on Sustaining Remission of Severe Depression: The STOP-PD II Study
Sites in Westchester: Weill Cornell Medical College – 914-997-5721;
Manhattan: Weill Cornell Medical College – 212-746-3979;
and UMass: 508-856-5928.
The original STOP-PD study established that the combination of olanzapine and sertraline was significantly better than olanzapine alone in achieving remission of psychotic depression. This STOP-PD-II Sustaining Remission study aims to assess the long-term tolerability of taking this combination of medications and their efficacy at preventing a relapse of the symptoms. The acute phase of the study will monitor the efficacy and tolerability of the olanzapine and sertraline combination, including investigation of weight and metabolic variables, age effects on treatment response and tolerability, and the association of genetic polymorphisms to response or relapse. When subjects are stabilized on these medications for a period of 8 weeks they will be invited to participate in the randomized phase of the research: the olanzapine will be placebo-controlled, meaning half of the subjects will continue to take the olanzapine/sertraline combination and half will take a sertraline/placebo combination, for a period of 36 weeks. Symptoms and side effects will be monitored regularly throughout this phase.
Diagnosed with Schizophrenia and Previous Trouble with the Law?
You are not alone. More people with serious mental illness in this country are in jails and prisons than in hospitals.
If this is you or someone you know then learn about the PRIDE study — a research study especially for people diagnosed with schizophrenia who have had trouble with the law.
This study is being conducted by the Hospital of Central Connecticut
If you think you qualify and would like to find out more, please contact: Alison Oville, Clinical Research Manager, The Hospital of Central Connecticut, (860)-224-5597, aoville@THOCC.org
For more information about participating in this study, click HERE
Providers: For a full color flyer that you can post in your facility, click HERE
The SearchLyte Research Program For People Living With Schizophrenia
Dear NAMI Connecticut Members:
As you may be aware, it is believed that approximately 20% of schizophrenia patients experience predominant negative symptoms (such as feeling numb or empty inside, feeling that others are talking about you, hearing noises or voices that others don’t hear, seeing things that others may not experience, and having difficulty organizing your thoughts or making people understand you and finding it hard to communicate), which often persist despite antipsychotic treatment. There is therefore an urgent medical need for the development of treatments specifically targeted at the negative symptoms of schizophrenia.
Three of the studies in the SearchLyte Program are looking at whether a potential new investigational treatment, RO4917838, is effective and safe in treating the negative symptoms of schizophrenia when given with a patient’s usual antipsychotic medication.
All participants will continue to take their usual antipsychotic medication during the study. In addition, participants will be given either the investigational medication or placebo (a sugar pill) to take every day. The study will last for just over a year and will include approximately 20 visits to the clinic. During these visits, doctors and nurses will carry out several checks. If possible, your caregiver (someone you see for more than 4 hours every week) should accompany you at these visits, should you choose to take part in the study. After that there will be an opportunity to receive the investigational study medication for a longer period of up to 3 years.
To be eligible for the study, patients need to be age 18 or older and currently taking a typical or atypical antipsychotic (not clozapine); they must have been clinically stable for 5 months, and have a responsible caregiver who can ensure compliance with the study and its procedures. Participants need to have prominent and persistent negative symptoms despite taking their antipsychotic medications.
For more information, please contact: Andrew Winokur, MD, PhD, Principal Investigator; The SearchLyte Study Team; (860) 545-7956 or (860) 545-7502.